Tina Liedtky: Thermo Fisher Scientific Launches New Test to Help Guide Tacrolimus Dosing
Tina Liedtky, President of the Transplant Diagnostics Division at Thermo Fisher Scientific, shared a post on LinkedIn:
“In transplant medicine, every patient is unique. And healthcare teams need tools that enable them to provide personalized care.
To this end, I am excited to share that, today, Thermo Fisher Scientific launched a new laboratory developed test to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug that can help lower the risk of transplant rejection.
The right tacrolimus dose will vary from patient to patient.
With the new TacroType Pharmacogenetic Test, clinicians can better understand how their patient is likely to metabolize tacrolimus and respond to certain therapies.
This pharmacogenetic information is invaluable.
Learn more about what the new TacroType Pharmacogenetic Test means for patient care by reading the press release.”
Stay updated with Hemostasis Today.
-
Apr 15, 2026, 14:29Joseph Caprini: The Future of VTE Care Is Shifting from Static Risk to Digital Twins
-
Apr 15, 2026, 14:25Prince Alfred Singh։ Understanding Antithrombin III Deficiency as a High-Risk Thrombophilia
-
Apr 15, 2026, 14:16Erin VanDyke: Next Generation Is Leading the Way in Pediatric VTE Care
-
Apr 15, 2026, 14:13Shahzeb Hassan: Pulmonary Embolism – What to Do When Every Minute Matters
-
Apr 15, 2026, 14:06Hossam El Benawi: Intensive Blood Pressure Reduction May Worsen Outcomes After Thrombectomy
-
Apr 15, 2026, 13:51Matías J Alet: Hospital Carlos Saporiti on the Path to Essential Stroke Center Recognition
-
Apr 15, 2026, 13:39Congratulations to Sandy Middleton for Taking the 2026 HESTA Australian Nursing and Midwifery Awards – Stroke Foundation
-
Apr 15, 2026, 13:25Wolfgang Miesbach: Platelet Variation and How Do They Move Over Time?
-
Apr 15, 2026, 12:44Marwa Elnahas: 4Ts Scoring Tool for Heparin – Induced Thrombocytopenia